Advertisement
AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

AJPH First Look, published online ahead of print Feb 28, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
AJPH.2006.107169v1
97/4/589    most recent
Right arrow Submit a response
Right arrow purchase articles
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Get other permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ross, L. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ross, L. F.
Related Collections
Right arrow Ethics
Right arrow Public Health Practice
Right arrow African Americans/Blacks
Right arrow Hispanics/Latinos
April 2007, Vol 97, No. 4 | American Journal of Public Health 589
© 2007 American Public Health Association
DOI: 10.2105/AJPH.2006.107169

LETTER

METHODOLOGY MATTERS

Lainie Friedman Ross, MD, PhD

Lainie Friedman Ross is with the Section of Community Health Sciences in the Institute for Molecular Pediatric Sciences and the MacLean Center for Clinical Medical Ethics, University of Chicago, Chicago, Ill.

Correspondence: Request for reprints should be sent to Lainie F. Ross, University of Chicago, Department of Pediatrics, 5841 S. Maryland Ave, MC 6082, Chicago, IL 60637 (e-mail: lross@uchicago.edu).

Because this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

I want to thank Green et al. for discussing important challenges and complexities in newborn screening (NBS).1 However, in their review of NBS for cystic fibrosis, Green et al. only considered programs that applied an immunoreactive tryspsinogen (IRT) screen that "triggered genetic analysis"1(p1957) for those with a positive screen. As Green et al. realize, although most US programs use an IRT/DNA methodology, not all do so.2 Rather, some use an IRT/IRT method, although this method has the disadvantage of requiring a second blood sample.2 However, there has been some work on using a pancreatitis-associated protein enzyme-linked immunosorbent assay combined with . . . [Full Text]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Public Health Association